-+ 0.00%
-+ 0.00%
-+ 0.00%

MAPLIGHT THERAPEUTICS - TO PROCEED WITH ADDITIONAL REGISTRATIONAL TRIAL AND ENGAGE FDA AT END-OF-PHASE 2

Reuters·07/27/2026 11:00:02

Please log in to view news